Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.
- Revenue in USD (TTM)22.60bn
- Net income in USD14.64bn
- Incorporated2016
- Employees2.70k
- LocationModerna Inc200 Technology SqCambridge 02139-3578United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AmerisourceBergen Corp. | 229.67bn | 1.73bn | 31.65bn | 38.00k | 18.46 | 57.50 | 13.14 | 0.1378 | 8.19 | 8.19 | 1,089.89 | 2.63 | 4.40 | 15.57 | 13.16 | 6,043,852.00 | 3.33 | 0.1634 | 12.41 | 0.6614 | 3.52 | 2.89 | 0.7561 | 0.0365 | 0.5583 | 13.78 | 0.8769 | 473.09 | 12.69 | 7.82 | 145.18 | 1.52 | -1.16 | 5.29 |
| DuPont de Nemours Inc | 15.95bn | 1.43bn | 32.69bn | 28.00k | 23.53 | 1.25 | 11.26 | 2.05 | 2.73 | 2.99 | 30.59 | 51.47 | 0.3423 | 4.39 | 6.46 | 569,678.60 | 3.21 | -0.2227 | 3.68 | -0.289 | 34.79 | 31.60 | 9.37 | -1.61 | 2.38 | 5.44 | 0.2918 | -- | 16.15 | -19.13 | 172.14 | -15.09 | -25.20 | -26.30 |
| Iqvia Holdings Inc | 14.03bn | 1.08bn | 37.34bn | 79.00k | 35.57 | 6.31 | 16.40 | 2.66 | 5.55 | 5.55 | 72.09 | 31.27 | 0.5677 | -- | 5.64 | 177,632.90 | 4.37 | 1.77 | 5.53 | 2.14 | 33.99 | 34.30 | 7.70 | 3.64 | -- | 4.43 | 0.681 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| McKesson Corporation | 263.97bn | 1.12bn | 46.61bn | 58.00k | 44.80 | -- | 22.72 | 0.1766 | 7.16 | 7.12 | 1,703.28 | -15.67 | 4.11 | 13.21 | 13.98 | 4,551,138.00 | 2.01 | -0.7548 | 7.65 | -2.38 | 5.03 | 5.24 | 0.4895 | -0.2014 | 0.568 | 40.83 | 1.44 | -- | 10.80 | 5.86 | 124.66 | -26.44 | -0.9799 | 9.71 |
| Moderna Inc | 22.60bn | 14.64bn | 54.78bn | 2.70k | 4.05 | 3.23 | 3.67 | 2.42 | 34.01 | 34.01 | 52.50 | 42.69 | 1.12 | 2.83 | 7.08 | 8,370,371.00 | 72.64 | 41.17 | 129.40 | 66.78 | 84.77 | -- | 64.77 | 52.35 | 1.56 | -- | 0.0451 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
| Vertex Pharmaceuticals Incorporated | 7.95bn | 2.45bn | 64.54bn | 3.90k | 26.59 | 5.91 | 24.98 | 8.12 | 9.49 | 9.49 | 30.70 | 42.68 | 0.6028 | 3.00 | 7.00 | 2,037,845.00 | 18.59 | 18.01 | 22.04 | 21.87 | 87.95 | 87.77 | 30.84 | 29.17 | 4.60 | 47.32 | 0.0435 | 0.00 | 22.06 | 34.79 | -13.63 | -- | 32.96 | -- |
| Regeneron Pharmaceuticals Inc | 16.51bn | 7.93bn | 72.41bn | 10.37k | 9.34 | 3.62 | 8.80 | 4.39 | 70.56 | 70.56 | 146.35 | 181.86 | 0.7483 | 1.62 | 3.66 | 1,592,216.00 | 35.96 | 25.64 | 41.87 | 29.99 | 84.65 | 88.51 | 48.06 | 39.11 | 4.27 | 360.50 | 0.1194 | -- | 89.14 | 27.02 | 129.86 | 55.24 | 1.52 | -- |
| Zoetis Inc | 7.89bn | 2.07bn | 74.76bn | 12.10k | 36.45 | 16.07 | 29.63 | 9.47 | 4.36 | 4.36 | 16.59 | 9.89 | 0.5707 | 1.23 | 6.72 | 652,148.80 | 14.97 | 13.79 | 18.36 | 16.04 | 70.76 | 68.75 | 26.23 | 23.94 | 1.58 | 11.50 | 0.5854 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Gilead Sciences, Inc. | 27.47bn | 4.52bn | 79.30bn | 14.40k | 17.66 | 3.98 | 12.03 | 2.89 | 3.58 | 3.58 | 21.78 | 15.88 | 0.4208 | 4.09 | 7.12 | 1,907,778.00 | 6.88 | 8.35 | 8.00 | 10.02 | 75.74 | 79.56 | 16.35 | 22.22 | 1.30 | 7.42 | 0.5682 | 58.76 | 10.60 | -2.12 | 4,960.98 | -14.34 | -4.99 | 9.07 |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Mar 2022 | 45.63m | 11.32% |
| The Vanguard Group, Inc.as of 31 Mar 2022 | 25.61m | 6.36% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 19.89m | 4.94% |
| SSgA Funds Management, Inc.as of 31 Dec 2021 | 14.86m | 3.69% |
| Geode Capital Management LLCas of 31 Mar 2022 | 6.44m | 1.60% |
| Th�l�me Partners LLPas of 31 Mar 2022 | 6.34m | 1.57% |
| Coatue Management LLCas of 31 Dec 2021 | 4.29m | 1.06% |
| Renaissance Technologies LLCas of 31 Mar 2022 | 3.82m | 0.95% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2022 | 3.50m | 0.87% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 3.04m | 0.76% |
